NCT06142396 2026-03-12
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
Augusta University
Phase EARLY_PHASE1 Recruiting
Clinical Trials
8 trialsNCT04265872 2026-02-12
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
Baylor Research Institute
Phase EARLY_PHASE1 Recruiting
NCT01594242 2019-04-16
Autophagy Induction After Bortezomib for Myeloma
Abramson Cancer Center at Penn Medicine
Phase EARLY_PHASE1 Completed
NCT01171092 2017-01-11
A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma
University of Kansas Medical Center
Phase EARLY_PHASE1 Completed
NCT02109861 2015-12-08
Phase-0-MM
Aalborg University Hospital
Phase EARLY_PHASE1 Unknown
NCT01537861 2015-01-26
Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma
Washington University School of Medicine
Phase EARLY_PHASE1 Terminated
NCT00437086 2014-10-17
Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT00515138 2012-04-12
A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant
University of California, San Francisco
Phase EARLY_PHASE1 Terminated